Skip to main content

Advertisement

SpringerLink
Log in

Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy

Organ System Program, National Cancer Institute

  • Special Report
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Proceedings of the 9th International Conference on Brain Tumor Research and Therapy: 1. Introduction; 2. Surgery; 3. Radiation therapy; 4. Chemotherapy; 5. Immunotherapy; 6. Growth-regulatory alterations; 7. Molecular genetics; 8. Brain tumor invasion; 9. Normal tissue damage; 10. Polyamines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. DeVita VT: The relationship between tumor mass and resistance to chemotherapy: implications for surgical adjuvant treatment of cancer. Cancer 51: 1209–1220, 1983

    PubMed  Google Scholar 

  2. Griswold DP Jr: Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence. Cancer Treat Rep 70: 81–86, 1986

    PubMed  Google Scholar 

  3. Ammirati M, Galicich JH, Arbit Eet al.: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21: 607–614, 1987

    PubMed  Google Scholar 

  4. Levin VA, Wara WM, Davis RLet al.: Northern California Oncology Group Protocol 6G91: response to treatment with radiation therapy and seven-drug chemotherapy in patients with glioblastoma multiforme. Cancer Treat Rep 70: 739–743, 1986

    PubMed  Google Scholar 

  5. Shapiro WR, Green SB, Burger PC, Mahaley MS Jr, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA, Pistenmaa DA: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71: 1–9, 1989

    Google Scholar 

  6. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 71: 487–493, 1989

    PubMed  Google Scholar 

  7. Andreou J, George AE, Wise Aet al.: CT prognostic criteria of survival after malignant glioma surgery. AJNR Am J Neuroradiol 4: 488–490, 1983

    PubMed  Google Scholar 

  8. Levin VA, Hoffman WF, Heilbron DC, Norman D: Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. J Neurosurg 52: 642–647, 1980

    PubMed  Google Scholar 

  9. Wood JR, Green SB, Shapiro WR: The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6: 338–343, 1988

    PubMed  Google Scholar 

  10. Murovic J, Turowski K, Wilson CB, Hoshino T, Levin V: Computerized tomography in the prognosis of malignant cerebral gliomas. J Neurosurg 65: 799–806, 1986

    PubMed  Google Scholar 

  11. Wilson CB: Glioblastoma the past, the present, and the future. Clin Neurosurg 38: 32–48, 1992

    PubMed  Google Scholar 

  12. Sheline GE: Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys 18: 793–803, 1990

    PubMed  Google Scholar 

  13. Keim H, Potthoff PC, Schmidt Ket al.: Survival and quality of life after continuous accelerated radiotherapy of glioblastomas. Radiother Oncol 9: 21–26, 1987

    PubMed  Google Scholar 

  14. Taghian A, Suit H, Pardo Fet al.:In vitro intrinsic radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 23: 55–62, 1992

    PubMed  Google Scholar 

  15. Wilson GD: Assessment of human tumour proliferation using bromodeoxyuridine — current status. Acta Oncol1 30: 903–910, 1991

    PubMed  Google Scholar 

  16. Shenouda G, Souhami L, Freeman CRet al.: Accelerated fractionation for high-grade cerebral astrocytomas. Preliminary treatment results. Cancer 67: 2247–2252, 1991

    PubMed  Google Scholar 

  17. Edwards MSB, Wara WM, Urtasun RC, Prados M, Levin VA, Fulton D, Wilson CB, Hannigan J, Silver P: Hyperfractionated radiation therapy for brain-stem glioma: a phase I–II trial. J Neurosurg 70: 691–700, 1989

    PubMed  Google Scholar 

  18. Freeman CR, Krischer J, Sanford RAet al.: Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 15: 311–318, 1988

    PubMed  Google Scholar 

  19. Freeman CR, Krischer J, Sanford RAetal.: Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495. Cancer 68: 474–481, 1991

    PubMed  Google Scholar 

  20. Packer RJ, Allen JC, Goldwein JLet al.: Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7,200 cGy. Ann Neurol 27: 167–173, 1990

    PubMed  Google Scholar 

  21. Prados M, Edwards M, Wara Wet al.: Hyperfractionated radiotherapy in the management of patients with medulloblastoma (Abstract). J Neurooncol 12: 263, 1992

    Google Scholar 

  22. Allen C, Nirenberg A, Donahue B: Hyperfractionated radiotherapy and adjuvant chemotherapy for high risk PNET (Abstract). J Neurooncol 12: 262, 1992

    Google Scholar 

  23. Kun LE, Fontanesi J, Kovnar Eet al.: Hyperfractionated craniospinal irradiation—A phase I trial in children with malignant central nervous system tumors. Pediatr Neurosurg 16: 112, 1991

    Google Scholar 

  24. Halberg FE, Wara WM, Fippin LFet al.: Low-dose craniospinal radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 20: 651–654, 1991

    PubMed  Google Scholar 

  25. Kun LE, Constine LS: Medulloblastoma — caution regarding new treatment approaches (Editorial). Int J Radiat Oncol Biol Phys 20: 897–899, 1991

    PubMed  Google Scholar 

  26. Gutin PH, Prados MD, Phillips TLet al.: External irradiation followed by an interstitial high activity iodine-125 implant ‘boost’ in the initial treatment of malignant gliomas. NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 21: 601–606, 1991

    PubMed  Google Scholar 

  27. Leibel SA, Gutin PH, Wara WMet al.: Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 17: 1129–1139, 1989

    PubMed  Google Scholar 

  28. Loeffler JS, Alexander E 3d, When PYet al.: Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 82: 1918–1921, 1990

    PubMed  Google Scholar 

  29. Loeffler JS, Rossitch E Jr, Siddon Ret al.: Role of stereotactic radiosurgery with a linear accelerator in treatment of intracranial arteriovenous malformation and tumors in children. Pediatrics 85: 774–782, 1990

    PubMed  Google Scholar 

  30. Lunsford LD, Flickinger J, Coffey RJ: Stereotactic gamma knife radiosurgery. Initial North American experience in 207 patients. Arch Neurol 47: 169–175, 1990

    PubMed  Google Scholar 

  31. Schwade JG, Houdek PV, Landy HJet al.: Small-field stereotactic external-beam radiation therapy of intracranial lesions: fractionated treatment with a fixed-halo immobilization device. Radiology 176: 563–565, 1990

    PubMed  Google Scholar 

  32. Photon Treatment Planning Collaborative Working Group: Three-dimensional display in planning radiation therapy: a clinical perspective. Int J Radiat Oncol Biol Phys 21: 79–89, 1991

    Google Scholar 

  33. Evans RG, Kimler BF, Morantz RAet al.: A phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors. Int J Radiat Oncol Biol Phys 19: 415–420, 1990

    PubMed  Google Scholar 

  34. Kimler BF, Evans RG, Morantz RAet al.: Lack of long-term complications subsequent to the use of Fluosol and oxygen as adjuvant to radiation therapy for high-grade malignant brain tumors (Abstract). J Neurooncol 12: 265, 1992

    Google Scholar 

  35. Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS: Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 75: 559–563, 1991

    PubMed  Google Scholar 

  36. Phillips TL, Levin VA, Ahn DKet al.: Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center phase II study. Int J Radiat Oncol Biol Phys 21: 709–714, 1991

    PubMed  Google Scholar 

  37. Malaise EP, Fertil B, Chavaudra Net al.: Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison ofin vitro toin vivo data. Int J Radiat Oncol Biol Phys 12: 617–624, 1986

    PubMed  Google Scholar 

  38. Peters LJ: The ESTRO Regaud lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol 17: 177–190, 1990

    PubMed  Google Scholar 

  39. Byar DP, Green SB, Strike TA: Prognostic factors for malignant glioma. In: Walker MD (ed) Oncology of the Nervous System, Martinus Nijhoff, Boston, 379–395, 1983

    Google Scholar 

  40. Evans AE, Jenkin RDT, Sposto R, Ortega JA, Wilson CB, Wara W, Ertel IJ, Kramer S, Chang CH, Leikin SL, Hammond GD: The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72: 572–582, 1990

    PubMed  Google Scholar 

  41. Hughes PG: Cerebellar medulloblastoma in adults. J Neurosurg 60: 994–997, 1984

    PubMed  Google Scholar 

  42. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, Mealey J Jr, Ransohoff J, Mahaley MS Jr: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76: 772–781, 1992

    PubMed  Google Scholar 

  43. Eyre HJ, Jaeckle K, Green SJet al.: AZQ 24-hour infusion vs BCNU for adult high-grade gliomas: preliminary results of SWOG-8737 (Abstract). J Neurooncol 12: 241, 1992

    Google Scholar 

  44. Schold C: Recent CNS Cancer Consortium trials with AZQ, mitomycin, 6-mercaptopurine, cyclophosphamide, and intracarotid cisplatin (Abstract). J Neurooncol 12: 241, 1992

    Google Scholar 

  45. Buckner J, Cascino T, Shaw Eet al.: Clinical trials in brain tumors: Mayo Clinic/North Central Cancer Treatment Group (NCCTG) (Abstract). J Neurooncol 12: 242, 1992

    Google Scholar 

  46. Jaeckle KA, Black KL, LaSala Pet al.: Phase II multicenter trial of serratia biologic response modifier (S-BRM) in recurrent malignant astrocytomas (MA) (Abstract). J Neurooncol 12: 242, 1992

    Google Scholar 

  47. Duffner P, Horowitz M, Krischer Jet al.: Postoperative chemotherapy and delayed RT in infants with brain tumors: a Pediatric Oncology Group study (Abstract). J Neurooncol 12: 249, 1992

    Google Scholar 

  48. Levin VA, Silver P, Hannigan Jet al.: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321–324, 1990

    PubMed  Google Scholar 

  49. Levin VA, Wara WM, Gutin PHet al.: Initial analysis of NCOG 6G82-1: bromodeoxyuridine (BUdR) during irradiation followed by CCNU, procarbazine, and vincristine (PCV) chemotherapy for malignant gliomas (Abstract). Proc Am Soc Clin Oncol 9: 91, 1990

    Google Scholar 

  50. Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10: 766–771, 1992

    PubMed  Google Scholar 

  51. Rozental JM, Robins HI, Finlay Jet al.: ‘Eight-drugs-in-one-day’: chemotherapy administered before and after radiotherapy to adult patients with malignant gliomas. Cancer 63: 2475–2481, 1989

    PubMed  Google Scholar 

  52. Finlay A: An update on the brain tumor trials of the Children's Cancer Study Group (CCSG) (Abstract). J Neurooncol 12: 239, 1992

    Google Scholar 

  53. Friedman H, Kun LE, POG Brain Tumor Core Committee: Pediatric Oncology Group (POG) brain tumor progress report (Abstract). J Neurooncol 12: 239, 1992

    Google Scholar 

  54. Kretschmar C, Tarbell N, Barnes Pet al.: Pre-radiation chemotherapy (chemorx) for children with pontine gliomas (Abstract). J Neurooncol 12: 266, 1992

    Google Scholar 

  55. Packer RJ: Régional and NCI Working-Group trials in children with brain tumors (Abstract). J Neurooncol 12: 240, 1992

    Google Scholar 

  56. Deutsch M, Thomas P, Boyette Jet al.: Low-stage medulloblastoma: a Children's Cancer Study Group (CCSG) and Pediatric Oncology Group (POG) randomized study of standard versus reduced neuro-axis irradiation (Abstract). Proc Am Soc Clin Oncol 10: 124, 1991

    Google Scholar 

  57. Bailey CC, Gwentow AK, Michaelis Jet al.: SIOP II/GPO Med.84 Medulloblastoma trial annual status report 1991 (Abstract). J Neurooncol 12: 240, 1992

    Google Scholar 

  58. Kühl J: Preliminary results of the German pilot trial hit 88/89 in children and young adults with medulloblastoma (Abstract). J Neurooncol 12: 240, 1992

    Google Scholar 

  59. Levin VA, Prados MD, Yung WKAet al.: Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84: 1432–1437, 1992

    PubMed  Google Scholar 

  60. Grimm EA, List J, Loudon WGet al.: Cellular immune response in the human brain: cytokine cascade in the CSF after intraventricular IL-2 injection (Abstract). J Neurooncol 12: 252, 1992

    Google Scholar 

  61. Miyatake S-I, Nishihara K, Kibuchi H: Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with IFN-γ gene (Abstract). J Neurooncol 12: 281, 1992

    Google Scholar 

  62. Moser RP, Gingras MC, Bruner JMet al.: Lymphocyte recruitment and trafficking in brain tumors (Abstract). J Neurooncol 12: 268, 1992

    Google Scholar 

  63. Rosenberg SA: Immunotherapy and gene therapy of cancer. Proc Am Assoc Cancer Res 81 (Suppl): 5074s-5079s, 1991

    Google Scholar 

  64. Rice CD, Merchant RE, Young HF: Recombinant interleukin-1β increases survival of rats with glioma by stimulating leukocytic infiltration and inhibiting angiogenesis (Abstract). J Neurooncol 12: 281, 1992

    Google Scholar 

  65. Merchant RE, Davis D, Young HF: Immunotherapy for recurrent primary CNS malignancy using recombinant IL-2 plus systemic Roferon-A (Abstract). J Neurooncol 12: 267, 1992

    Google Scholar 

  66. List J, Moser RP, Steuer Met al.: Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 6, gamma-interferon, and soluble interleukin-2 receptor (Mr 55,000 protein). Cancer Res 52: 1123–1128, 1992

    PubMed  Google Scholar 

  67. Sawamura Y, Tada M, Sakuma Set al.: Intracranial administration of TNF-α elicits multiple immune responses in the central nervous system bearing malignant glioma (Abstract). J Neurooncol 12: 269, 1992

    Google Scholar 

  68. Bigner DD, Wong A, Vogelstein Bet al.: Highly specific polyclonal and monoclonal antibodies against epidermal growth factor receptor mutant proteins of malignant astrocytic gliomas (MAG) (Abstract). J Neurooncol 12: 251, 1992

    Google Scholar 

  69. Fredman P, Wikstrand CJ, Svennerholm Let al.: Epitope specificity of monoclonal antibodies to glioma associated gangliosides and the quantitative measurement of these antigens in normal brain and brain tumors (Abstract). J Neurooncol 12: 251, 1992

    Google Scholar 

  70. Wikstrand CJ, Fredman P, Svennerholm Let al.: Expression of gangliosides GM2, GD2, GD3, 3′-isoLM1, and 3′,6′isoLD1 in CNS malignancies as defined by epitope-characterized monoclonal antibodies (Mabs) (Abstract). J Neurooncol 12: 251, 1992

    Google Scholar 

  71. Zalutsky MR, Garg PK, Archer GEet al.: Therapeutic efficacy of anti-tenascin antibody 81C6 labeled with I-131 and AT-211 (Abstract). J Neurooncol 12: 251, 1992

    Google Scholar 

  72. Fuchs HE, Archer GE, Schuster JMet al.: A nude rat model of neoplastic meningitis for evaluation of intrathecal chemotherapy and monoclonal antibody (MAb)-based radiotherapy (Abstract). J Neurooncol 12: 278, 1992

    Google Scholar 

  73. Moseley RP, Lashford LS, Coakham HBet al.: Intrathecal radioimmunoconjugate therapy for neoplastic meningitis (Abstract). J Neurooncol 12: 252, 1992

    Google Scholar 

  74. Papanastassiou V, Tzanis S, Pizer Bet al.: Targeted radiation therapy for malignant glioma (Abstract). J Neurooncol 12: 268, 1992

    Google Scholar 

  75. Brady LW, Markoe AM, Woo DVet al.: Iodine-125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. J Neurosurg Sci 34: 243–249, 1990

    PubMed  Google Scholar 

  76. Moseley RP, Davies AG, Richardson RBet al.: Intrathecal administration of131I-labelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer 62: 637–642, 1990

    PubMed  Google Scholar 

  77. Riva P, Arista A, Sturiale Cet al.: Treatment of intracranial human glioblastoma by direct intratumoral administration of131I-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer 51: 7–13, 1992

    PubMed  Google Scholar 

  78. Yu AL, Reisfeld RA, Gillies SD: Immune response to monoclonal anti-GD2 antibody therapy (Abstract). Proc Am Assoc Cancer Res 32: 263, 1991

    Google Scholar 

  79. Khazaeli MB, Saleh MN, Liu TPet al.: Pharmacokinetics and immune response of 131-I-chimeric mouse/human B72.3 (human gamma-4) monoclonal antibody in humans. Cancer Res 51: 5461–5466, 1991

    PubMed  Google Scholar 

  80. Baker T, Begent R, Divgi Met al.: Characterization of the antibody response in patients undergoing radiotherapy with chimeric B72.3 (Abstract). Antibody Immunoconjugates Radiopharmaceuticals 4: 39A, 1991

    Google Scholar 

  81. LoBuglio A, Wheeler R, Trang Jet al.: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 88: 4220–4224, 1989

    Google Scholar 

  82. Meredith R, LoBuglio A, Plott Wet al.: Pharmacokinetics, immune response, and biodistribution of 121-I-labeled chimeric mouse/human IgG1, kappa 17-1A monoclonal antibody. J Nucl Med 32: 1162–1168, 1991

    PubMed  Google Scholar 

  83. Bigner SH, Burger PC, Wong Net al.: Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol 47: 191–205, 1988

    PubMed  Google Scholar 

  84. Wong N, Bigner SG, Bigner DDet al.: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 84: 6899–6903, 1987

    PubMed  Google Scholar 

  85. Humphrey PA, Wong N, Vogelstein Bet al.: Anti-synthetic peptide antibody reacting at the fission junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87: 4207–4211, 1990

    PubMed  Google Scholar 

  86. Maiden LT, Novak U, Kaye AKet al.: Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 48: 2711–2714, 1988

    PubMed  Google Scholar 

  87. Steck PA, Lee P, Hung MCet al.: Expression of an altered epidermal growth factor receptor by cultured human glioblastoma cell. Cancer Res 48: 5433–5439, 1988

    PubMed  Google Scholar 

  88. Yung WKA, Bruner JM, Steck PA: High molecular weight TGF-a in human gliomas (Abstract). Proc Am Assoc Cancer Res 32: 51, 1991

    Google Scholar 

  89. Yung WKA, Taylor S, Kim Yet al.: Expression and biological activity of transforming growth factor-alpha (TGF-α) in human glioma (Abstract). Proc Am Assoc Cancer Res 31: 45, 1990

    Google Scholar 

  90. Yung WKA, Zhang X, Steck PAet al.: Differential amplification of the TGF-alpha gene in human gliomas. Cancer Commun 2: 201–206, 1990

    PubMed  Google Scholar 

  91. Nister M, Wedell B, Betsholtz Cet al.: Evidence for progressional changes in the human malignant glioma line U-343 MGa: analysis of karyotype and expression of genes encoding the subunit chains of platelet-derived growth factor. Cancer Res 47: 4953–4960, 1987

    PubMed  Google Scholar 

  92. Mapstone T, McMichael M, Goldthwait D: Expression of platelet-derived growth factors, transforming growth factors, and ros gene in a variety of primary human brain tumors. Neurosurgery 28: 216–222, 1991

    PubMed  Google Scholar 

  93. Nister M, Libermann TA, Petsholtz Cet al.: Expression of messenger RNAs for platelet-derived growth factor and transformed growth factor-α and their receptors in human malignant glioma cell lines. Cancer Res 48: 3910–3918, 1988

    PubMed  Google Scholar 

  94. Libermann TA, Friesel R, Lyall PMet al.: An angiogenic growth factor is expressed in human glioma cells. EMBO J 6: 1627–1632, 1987

    PubMed  Google Scholar 

  95. Morrison RS, Gross JL, Herlin WFet al.: Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res 50: 2524–2529, 1990

    PubMed  Google Scholar 

  96. Clark WC, Bressler J: Transforming growth factor-β-like activity in tumors of the central nervous system. J Neurosurg 68: 920–924, 1988

    PubMed  Google Scholar 

  97. Fontana A, Bodmer S, Frei K: Immunoregulatory factors secreted by astrocytes and glioblastoma cells. Lymphokines 14: 91–121, 1987

    Google Scholar 

  98. Jennings MT, Maciunas RJ, Carver Ret al.: TGF-β1 and TGF-β2 are potential growth regulators for low-grade and malignant gliomasin vitro: evidence in support of an autocrine hypothesis. Int J Cancer 49: 129–139, 1991

    PubMed  Google Scholar 

  99. Steck PA, Hadi A, Pershouse MAet al.: Cellular and molecular consequences of re-insertion of chromosome 10 into human glioblastoma (Abstract). Proc Am Assoc Cancer Res 33: 388, 1992

    Google Scholar 

  100. Saya H, Nishi T, Lee PSYet al.: Alternative approaches of the neurofibromatosis type l (NF1) gene transcript during neuronal differentiation. J Neurooncol 12: 256, 1992

    Google Scholar 

  101. Westermark B: Platelet-derived growth factor as a mitogen for normal and malignant cells in the central nervous system (Abstract). J Neurooncol 12: 255, 1992

    Google Scholar 

  102. Burger PC: Pathological and autopsy studies of glioblastoma multiforme (Abstract). J Neurooncol 12: 247, 1992

    Google Scholar 

  103. Burger PC, Dubois PJ, Schold SC Jr, Smith KR Jr, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58: 159–169, 1983

    PubMed  Google Scholar 

  104. Schiffer D, Bertolotto A, Giordana MTet al.: Spreading and invasion patterns of malignant gliomas (Abstract). J Neurooncol 12: 270, 1992

    Google Scholar 

  105. Kelly PJ, Daumas-Duport C, Scheithauer BWet al.: Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 62: 450–459, 1987

    PubMed  Google Scholar 

  106. Rosenblum ML, Eisenberg AD, Norman D: Brain tumor invasion: clinical patterns of malignant astrocytoma spread (Abstract). J Neurosurg 76: 383A, 1992

    Google Scholar 

  107. Wilson CB: Glioblastoma — a local disease (Abstract). J Neurooncol 12: 247, 1992

    Google Scholar 

  108. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907–911, 1980

    PubMed  Google Scholar 

  109. Massey V, Wallner KE: Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18: 395–398, 1990

    PubMed  Google Scholar 

  110. Loeffler JS, Alexander E III, Black PMet al.: The results of radiosurgery used in the management of newly diagnosed and recurrent malignant gliomas (Abstract). J Neurooncol 12: 248, 1992

    Google Scholar 

  111. Kemshead JT: Targeted approaches to developing highly specific reagents to tumours arising from the neuroectoderm (Abstract). J Neurooncol 12: 257, 1992

    Google Scholar 

  112. Kramer RH, Ramos D, Amar Aet al.: Invasive tumor cells use multiple integrin receptors during interaction with the extracellular matrix (Abstract). J Neurooncol 12: 257, 1992

    Google Scholar 

  113. McKerrow JH, Brown M, Wall Jet al.: The role of proteases in brain tumor invasion (Abstract). J Neurooncol 12: 257, 1992

    Google Scholar 

  114. Berens ME, Spencer DR, Rosenblum ML: Glioma-derived factors linked to invasion (Abstract). J Neurooncol 7 (Suppl): S5, 1989

    Google Scholar 

  115. Janzer RC: Blood-brain barrier breakdown in malignant gliomas may be mediated by the extracellular matrix secreted by tumor cells (Abstract). J Neurooncol 12: 279, 1992

    Google Scholar 

  116. Berens ME, Rief MD, Stachowiak MK: Novel epidermal growth factor receptor processing in human malignant glioma cells (Abstract). J Neurooncol 12: 273, 1992

    Google Scholar 

  117. Laerum OD, Pedersen P-H, Lund-Johansen Met al.: Growth factor and invasiveness of malignant gliomas (Abstract). J Neurooncol 12: 258, 1992

    Google Scholar 

  118. Pedersen P-H, Lund-Johansen M, Engebraaten Oet al.: Heterogenous response to growth factors (EGF, PDGF, TGF-α, IL-2) on glioma spheroid growth, migration and invasion (Abstract). J Neurooncol 12: 283, 1992

    Google Scholar 

  119. Liotta LA: Negative regulation of cancer invasion (Abstract). J Neurooncol 12: 260, 1992

    Google Scholar 

  120. Engebraaten O, Bjerkvig R, Mørkve Oet al.: GM2 ganglioside and p53 expression is linked to glioblastoma cell invasiveness (Abstract). J Neurooncol 12: 277, 1992

    Google Scholar 

  121. Rosenblum ML, Amar AP, Stowring LEet al.: Development ofin vitro andin vivo models to study human brain tumor invasion (Abstract). J Neurooncol 12: 272, 1992

    Google Scholar 

  122. Albini A, Iwamoto Y, Kleinman HKet al.: A rapidin vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239–3245, 1987

    PubMed  Google Scholar 

  123. Erkell LJ, Schirrmacher V: Quantitativein vitro assay for tumor cell invasion. Cancer Res 48: 6933–6937, 1988

    PubMed  Google Scholar 

  124. Kleinman HK, McGarvey ML, Hassell JRet al.: Basement membrane complexes with biological activity. Biochemistry 25: 312–318, 1986

    PubMed  Google Scholar 

  125. Bjerkvig R, Laerum OD, Mella O: Glioma cell interactions with fetal rat brain aggregatesin vitro and with brain tissuein vivo. Cancer Res 46: 4071–4079, 1986

    PubMed  Google Scholar 

  126. Bjerkvig R, Pedersen PH, Terzis AJAet al.: Tissue specific invasion of brain tumors (Abstract). J Neurooncol 12: 258, 1992

    Google Scholar 

  127. Engebraaten O, Bjerkvig R, Laerum ODet al.: Alkyl-lysophospholipid reduces human glioblastoma cell invasion (Abstract). J Neurooncol 12: 277, 1992

    Google Scholar 

  128. Terzis AJA, Bjerkvig R, Arnold Het al.: Interaction between human medulloblastoma and fetal rat brain aggregatesin vitro (Abstract). J Neurooncol 12: 286, 1992

    Google Scholar 

  129. Paganetti PA, Caroni P, Schwab ME: Glioblastoma infiltration into central nervous system tissuein vitro: involvement of a metalloprotease. J Cell Biol 107: 2281–2291, 1988

    PubMed  Google Scholar 

  130. Bernstein JJ, Goldberg WJ, Laws ER Jret al.: C6 glioma cell invasion and migration of rat brain after neural homografting ultrastructure. Neurosurgery 26: 622–628, 1992

    Google Scholar 

  131. Mella O, Bjerkvig R, Schem BCet al.: A cerebral glioma model for experimental therapy andin vivo invasion studies in syngeneic BD IX rats. J Neurooncol 9: 93–104, 1990

    PubMed  Google Scholar 

  132. Bernstein JJ, Goldberg WJ, Laws ER Jret al.: Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. J Neurosci Res 22: 134–145, 1989

    PubMed  Google Scholar 

  133. Apodaca G, Rutka JT, Bouhana Ket al.: Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50: 2322–2329, 1990

    PubMed  Google Scholar 

  134. Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054s-5059s, 1991

    PubMed  Google Scholar 

  135. Gutin PH, Leibel SA, Sheline GE: Radiation Injury to the Nervous System. Raven Press, New York, 1991

    Google Scholar 

  136. van der Kogel AJ: Central nervous system radiation injury in small animal models. In: Gutin PH, Leibel SA, Sheline GE (eds) Radiation Injury to the Nervous System, Raven Press, New York, 91–111, 1991

    Google Scholar 

  137. Vaeth JM, Meyer JL: Radiation Tolerance of Normal Tissues. Frontiers of Radiation Therapy and Oncology series. Proceedings of the 23rd Annual San Francisco Cancer Symposium, San Francisco, CA, March 4–5,1988, Vol 23, Karger, Basel, 1989

    Google Scholar 

  138. van der Maazen RWM, Verhagen I, van der Kogel AJ: Anin vitro clonogenic assay to assess radiation damage in rat CNS glial progenitor cells. Int J Radiat Biol 58: 835–844, 1990

    PubMed  Google Scholar 

  139. van der Kogel AJ: Radiation tolerance of the CNS:in vivo andin vitro studies (Abstract). J Neurooncol 12: 260, 1992

    Google Scholar 

  140. Yamaguchi N, Yamashima T, Yamashita J: A histological and flow cytometric study of dog brain endothelial cell injuries in delayed radiation necrosis. J Neurosurg 74: 625–632, 1991

    PubMed  Google Scholar 

  141. Yamashita J, Yamaguchi N, Yamashima T: Endothelial injuries in delayed radiation necrosis of the brain in dogs (Abstract). J Neurooncol 12: 288, 1992

    Google Scholar 

  142. Koenig J, Goldstone AD, Lu CY: Blood-brain barrier breakdown in brain edema following cold injury is mediated by microvascular polyamines. Biochem Biophys Res Commun 55: 1039–1048, 1983

    Google Scholar 

  143. Gobbel GT, Fike JR: Cerebrovascular response of dog brain to focal irradiation and its modification by α-difluoromethylornithine (Abstract). J Neurooncol 12: 260, 1992

    Google Scholar 

  144. Gobbel GT, Marton LJ, Lamborn Ket al.: Modification of radiation-induced brain injury by α-difluoromethylornithine. Radiat Res 128: 306–315, 1991

    PubMed  Google Scholar 

  145. BErnstein M, Glen J, Parsons Ket al.: Modification of brachytherapy by acetylsalicylic acid (ASA) in a rat model (Abstract). J Neurooncol 12: 274, 1992

    Google Scholar 

  146. Prados M, Rodriguez L, Chamberlain Met al.: Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine. Neurosurgery 24: 806–809, 1989

    PubMed  Google Scholar 

  147. Levin VA, Chamberlain MC, Prados MDet al.: Phase I–II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. Cancer Treat Rep 71: 459–464, 1987

    PubMed  Google Scholar 

  148. Basu H, Pellarin M, Feuerstein BG: Interaction of N1,N19-bisethyl)amino-5,10,15-triazanonadecane (BE-4444) with DNA and its effects on growth, survival and polyamine levels (Abstract). J Neurooncol 12: 273, 1992

    Google Scholar 

  149. Bernacki RJ, Bergeron RJ, Porter CW: Antitumor activity of N,N′-bis(ethyl)spermine homologues against human MALME-3 melanoma xenografts. Cancer Res 52: 2424–2430, 1992

    PubMed  Google Scholar 

  150. Basu HS, Pellarin M, Feuerstein BG, Deen DF, Marton LJ: Effects of the polyamine analogs BE-3-7-3, 3-8-3, and BE-3-8-3 on human brain tumor cell growth and survival. Anticancer Res (In press)

Download references

Author information

Authors and Affiliations

  1. UCSF, University of California, San Francisco

    Dennis F. Deen, John R. Fike, Mark A. Israel, Laurence J. Marton, Mark L. Rosenblum & Charles B. Wilson

  2. National Cancer Institute, USA

    Andrew Chiarodo

  3. M.D. Anderson Cancer Center, USA

    Elizabeth A. Grimm, Victor A. Levin & W. K. Alfred Yung

  4. St. Jude Children's Research Hospital, USA

    Lawrence E. Kun

  5. Children's National Medical Center, USA

    Roger J. Packer

  6. Milton S. Hershey Medical Center, USA

    Anthony E. Pegg

  7. Massachusetts General Hospital, USA

    Herman D. Suit

  8. National Institute of Neurological Disorders and Stroke, USA

    Michael D. Walker

  9. Duke University, USA

    Carol J. Wikstrand

  10. Fox Chase Cancer Center, USA

    Albert J. Wong

Authors
  1. Dennis F. Deen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Chiarodo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth A. Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John R. Fike
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mark A. Israel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lawrence E. Kun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Victor A. Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Laurence J. Marton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roger J. Packer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Anthony E. Pegg
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mark L. Rosenblum
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Herman D. Suit
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Michael D. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Carol J. Wikstrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Charles B. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Albert J. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. W. K. Alfred Yung
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deen, D.F., Chiarodo, A., Grimm, E.A. et al. Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. J Neuro-Oncol 16, 243–272 (1993). https://doi.org/10.1007/BF01057041

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01057041

Key words

Search

Navigation